Avapritinib obtained excellent clinical data in Phase 2 trials for the treatment of patients with inert systemic hyperplasia

recently, Blueprint Medicines(http://announced that its oral KIT and PDGFR alpha inhibitor avapritinib, obtained excellent preliminary clinical data in the Phase 2trial(http://PIONEER for the treatment of patients with inert systemic hypertrophic hyperplasiaAbout Avapritinib
Avapritinib is a type 1 inhibitor that targets kinase-activated conformations and inhibits a variety of protein kinases that carry MUTATIONs in THE KIT and PDGFRA genesBlueprint Medicines was originally developed to treat advanced gastrointestinal mesothelioma (GIST) and advanced SMIn June 2017, Avapritinib was recognized by the U.SFDA(http://Breakthrough Therapy for the treatment of non-reprecision or metastatic GIST patients with PDGFR alpha D842V mutationsPreviously, the FDA also qualified avapritinib orphan drugs for the treatment of GIST and hyperblastomaIn June last year, Keystone Pharmaceuticals acquired the clinical development and promotion interests of avapritinib in ChinaThe studypioneer's Phase 2 trial was a randomized, double-blind, placebo-controlled group of clinical studiesTrial data as of November 12, 2019 showed that patients in the three different dose-based treatment groups of avapritinib had significantly and rapidly reduced serum trypsin levels compared to baselines and were maintainedThe data did not change at 12 weeks in patients in the placebo groupThe decrease in serum trypsin levels is part of the clinical remission assessment criteria for SM patients based on the IWG-MRT-ECNM standardBlueprint Medicines expects to begin screening patients in the second part of the PIONEER trial in the first half of 2020